Nanoviricides Inc (NNVC)

$1.05 +0.03 (2.94%)
Market Cap 26.04M
Revenue (ttm) 0.00
Net Income (ttm) -9.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 650,290
Avg Vol 358,556
Day's Range N/A - N/A
Shares Out 25.53M
Stochastic %K 18%
Beta 1.66
Analysts Strong Sell
Price Target $6.33

Company Profile

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gumm...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 937 6137
Address:
1 Controls Drive, Shelton, United States
STRAYNUT
STRAYNUT Sep. 13 at 9:24 PM
$NNVC Part 4: So why would the WHO hire the same two companies that have failed in earlier trials? The only rational answer is that the WHO wants to do something, even though the likelihood of success is not great. Since the two US Pharma's are more than likely being paid generous sums, unlike NNVC, which must pay its own way, they are willing to shoulder the embarrassment of continued failure.
0 · Reply
STRAYNUT
STRAYNUT Sep. 12 at 6:55 PM
$NNVC Part 3 Just to get a sense of our competition in the current PARTNERS trial, I researched an earlier PALM trial to combat the Ebola Zaire subtype, conducted with the exact same players, in Northeastern DRC in 2018-20. The primary objective of that trial was the "28 day mortality relative to the Control arm (Z Mapp)". Both Remdesivir Infusion and Z Mapp's Monoclonal Antibody Cocktail Infusion FAILED. Compared to NNVC's Oral Gummies, this technology represents the "Dark Ages" relative to bionanotechnology.
0 · Reply
STRAYNUT
STRAYNUT Sep. 10 at 10:30 PM
$NNVC Short Interest (08/31/26) Shares Sold Short 646,145 Change from Last -26.08% Percent of Float 2.59% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
STRAYNUT
STRAYNUT Sep. 10 at 9:36 PM
$NNVC Part 1 BPh's solution to the Ebola outbreak in the Eastern DRC is a trial that was started in early July and has already infused 300 patients, with 700 more patients required, according to the WHO. Called the PARTNERS trial, between Gilead Sciences and Mapp Bio, it is divided into 4 sub-groups: Control, MBP134 Infusion, Remdesivir Infusion, and the combo of the two drugs together. You would think if they had great results in these first 60 days, they would be forthcoming with that news.
0 · Reply
STRAYNUT
STRAYNUT Sep. 10 at 9:30 PM
$$NNVC Part 2 Now contrast that ineffectual effort with the need for a quick-acting drug, such as NV-387, which will cure the patient in a matter of days. The importance of that feature is apparent when you consider the speed in which this Bundibugyo strain of ebolavirus attacks the body. It takes only 21 days for an infected patient to develop symptoms (fever, headache, tiredness) and only another 21 days from confirming infection to death. Nano is the only biotech in the world that is poised to validate NV-387 in a short and decisive clinical trial, with sufficient Oral Gummies already on site.
0 · Reply
drkazmd65
drkazmd65 Sep. 10 at 12:44 PM
$NNVC - Agreed in principle. However, until the trial IS ACTUALLY underway, we are dead in the water here. I won't be satisfied until and unless there is a PR stating that dosing has commenced.
0 · Reply
Love1010
Love1010 Sep. 9 at 9:42 PM
$NNVC Straynut pumping so down she blows
0 · Reply
STRAYNUT
STRAYNUT Sep. 9 at 7:32 PM
$NNVC NNVC: Part 1. Let me describe to you the most probable winner in the quest for a drug that will improve survival from the rare Bundibugyo Ebolavirus now out of control in the Eastern 6 provinces of the Democratic Republic of Congo (DRC) where the untreated fatality rate is now 48% for adults and 60%+ for children. Only NNVC is offering an oral drug, NV-387, in contrast to others that are infusions, which is extremely advantageous in the epidemic scenario that is now unfolding.
0 · Reply
STRAYNUT
STRAYNUT Sep. 9 at 7:32 PM
$NNVC Part 2 The Oral Gummies are manufactured in six-packs at the Shelton, Ct. lab, and since they are administered one each morning by placing the Gummy on the tongue and simply letting it melt there without swallowing, you can imagine how easy it will be to scale to hundreds of patients at a time if need be. I assign a probability of 90% that it will work perfectly and require only 12 days (2 six-packs) to cure the infected patient, which will astound the medical community, and send the NNVC market cap, currently at $28 million, to at least $150-300 million overnight.
0 · Reply
STRAYNUT
STRAYNUT Sep. 9 at 7:27 PM
$NNVC This is a link to the Pan African Clinical Trials Registry (pactr.samrc.ac.za) database. The unique identification number for this clinical trial is PACTR202608748555077. https://pactr.samrc.ac.za/Search.aspx
0 · Reply
Latest News on NNVC
NanoViricides announces registration of Phase II trial of NV-387 in ebolavirus

2026-09-08T12:45:24.000Z - 6 days ago

NanoViricides announces registration of Phase II trial of NV-387 in ebolavirus

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

Sep 8, 2026, 8:30 AM EDT - 6 days ago

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

NanoViricides provides updateon Measles Drug Treatment Program

2026-08-31T12:45:32.000Z - 14 days ago

NanoViricides provides updateon Measles Drug Treatment Program

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

Aug 31, 2026, 8:30 AM EDT - 14 days ago

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

NanoViricides registers to sell 2.52M shares of common stock for holders

2026-08-21T20:35:14.000Z - 24 days ago

NanoViricides registers to sell 2.52M shares of common stock for holders

NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’

2026-08-18T12:40:10.000Z - 27 days ago

NanoViricides to begin Phase II trial of NV-387 in ebola ‘soon’

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Aug 18, 2026, 8:30 AM EDT - 27 days ago

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

NanoViricides receives regulatory approval for Phase II trial of NV-387

2026-08-10T12:35:59.000Z - 5 weeks ago

NanoViricides receives regulatory approval for Phase II trial of NV-387

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Aug 10, 2026, 8:30 AM EDT - 5 weeks ago

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

NanoViricides awaits regulatory approval to being Phase II trial of NV-387

2026-07-28T12:40:29.000Z - 6 weeks ago

NanoViricides awaits regulatory approval to being Phase II trial of NV-387

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

Jul 28, 2026, 8:30 AM EDT - 6 weeks ago

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

NanoViricides prices $3.8M registered direct offering

2026-07-24T12:10:37.000Z - 7 weeks ago

NanoViricides prices $3.8M registered direct offering

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

Jul 24, 2026, 8:00 AM EDT - 7 weeks ago

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial

2026-07-22T12:56:07.000Z - 7 weeks ago

NanoViricides applies for ACOREP approval to begin Phase II NV-387 trial

NanoViricides gets National Ethics Committee approval for Phase II NV-387 trial

2026-07-13T13:30:07.000Z - 2 months ago

NanoViricides gets National Ethics Committee approval for Phase II NV-387 trial

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Jul 13, 2026, 9:27 AM EDT - 2 months ago

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

Jul 8, 2026, 8:30 AM EDT - 2 months ago

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

NanoViricides initiated with an Outperform at Noble Capital

2026-07-06T13:30:07.000Z - 2 months ago

NanoViricides initiated with an Outperform at Noble Capital

NanoViricides advances towards Phase II clinical trial of NV-387

2026-07-06T12:45:15.000Z - 2 months ago

NanoViricides advances towards Phase II clinical trial of NV-387

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

Jul 6, 2026, 8:30 AM EDT - 2 months ago

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

NanoViricides granted Rare Pediatric Disease Drug designation for NV-387

2026-06-29T12:41:04.000Z - 2 months ago

NanoViricides granted Rare Pediatric Disease Drug designation for NV-387

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

Jun 29, 2026, 8:30 AM EDT - 2 months ago

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo

2026-06-22T13:35:44.000Z - 2 months ago

NanoViricides ships NV-387 oral gummies for Phase II trials to DR Congo

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

Jun 22, 2026, 9:30 AM EDT - 2 months ago

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

NanoViricides files to sell 1.33M shares of common stock for holders

2026-06-15T20:41:08.000Z - 3 months ago

NanoViricides files to sell 1.33M shares of common stock for holders

NanoViricides announces proposal approved by Pillar Committee in DRC

2026-06-15T12:41:50.000Z - 3 months ago

NanoViricides announces proposal approved by Pillar Committee in DRC

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

Jun 15, 2026, 8:30 AM EDT - 3 months ago

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

NanoViricides proposes Phase II trial of NV-387 gummies in Ebola

2026-06-08T12:48:36.000Z - 3 months ago

NanoViricides proposes Phase II trial of NV-387 gummies in Ebola

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

Jun 8, 2026, 8:30 AM EDT - 3 months ago

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

NanoViricides files $50M mixed securities shelf

2026-06-05T20:35:24.000Z - 3 months ago

NanoViricides files $50M mixed securities shelf

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

May 26, 2026, 8:30 AM EDT - 3 months ago

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

May 18, 2026, 11:55 PM EDT - 3 months ago

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

NanoViricides emphasizes need for Ebolavirus antiviral drug

2026-05-18T12:35:07.000Z - 3 months ago

NanoViricides emphasizes need for Ebolavirus antiviral drug

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

May 18, 2026, 8:30 AM EDT - 3 months ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

May 15, 2026, 8:35 AM EDT - 4 months ago

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

May 15, 2026, 8:00 AM EDT - 4 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

May 11, 2026, 8:30 AM EDT - 4 months ago

Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

May 6, 2026, 3:37 PM EDT - 4 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

May 4, 2026, 8:30 AM EDT - 4 months ago

NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Apr 21, 2026, 8:30 AM EDT - 4 months ago

Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Apr 7, 2026, 8:30 AM EDT - 5 months ago

Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

Apr 1, 2026, 8:30 AM EDT - 5 months ago

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

Mar 11, 2026, 8:30 AM EDT - 6 months ago

NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 12, 2026, 8:30 AM EST - 7 months ago

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

Feb 10, 2026, 8:30 AM EST - 7 months ago

Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

Feb 2, 2026, 8:30 AM EST - 7 months ago

NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

Jan 13, 2026, 8:30 AM EST - 8 months ago

NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

Dec 1, 2025, 8:30 AM EST - 9 months ago

NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

Nov 17, 2025, 8:30 AM EST - 10 months ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

Nov 14, 2025, 8:30 AM EST - 10 months ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 12, 2025, 5:01 PM EST - 10 months ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

Nov 11, 2025, 8:30 AM EST - 10 months ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

Nov 10, 2025, 8:30 AM EST - 10 months ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

Nov 5, 2025, 8:30 AM EST - 10 months ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Nov 3, 2025, 8:30 AM EST - 10 months ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

Oct 29, 2025, 8:45 AM EDT - 10 months ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

Oct 27, 2025, 8:45 AM EDT - 10 months ago

NanoViricides to Present at the PODD 2025 Conference in Boston on October 27

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

Oct 22, 2025, 8:45 AM EDT - 10 months ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

Oct 20, 2025, 8:45 AM EDT - 10 months ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

Oct 15, 2025, 8:45 AM EDT - 11 months ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

NanoViricides, Inc. Has Filed its Annual Report

Sep 30, 2025, 8:45 AM EDT - 11 months ago

NanoViricides, Inc. Has Filed its Annual Report

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 11, 2025, 8:30 AM EDT - 1 year ago

RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

Sep 9, 2025, 8:30 AM EDT - 1 year ago

NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Aug 18, 2025, 8:30 AM EDT - 1 year ago

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

Jul 30, 2025, 8:30 AM EDT - 1 year ago

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Jul 23, 2025, 8:30 AM EDT - 1 year ago

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

Jul 21, 2025, 6:30 AM EDT - 1 year ago

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

Jul 16, 2025, 8:30 AM EDT - 1 year ago

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

STRAYNUT
STRAYNUT Sep. 13 at 9:24 PM
$NNVC Part 4: So why would the WHO hire the same two companies that have failed in earlier trials? The only rational answer is that the WHO wants to do something, even though the likelihood of success is not great. Since the two US Pharma's are more than likely being paid generous sums, unlike NNVC, which must pay its own way, they are willing to shoulder the embarrassment of continued failure.
0 · Reply
STRAYNUT
STRAYNUT Sep. 12 at 6:55 PM
$NNVC Part 3 Just to get a sense of our competition in the current PARTNERS trial, I researched an earlier PALM trial to combat the Ebola Zaire subtype, conducted with the exact same players, in Northeastern DRC in 2018-20. The primary objective of that trial was the "28 day mortality relative to the Control arm (Z Mapp)". Both Remdesivir Infusion and Z Mapp's Monoclonal Antibody Cocktail Infusion FAILED. Compared to NNVC's Oral Gummies, this technology represents the "Dark Ages" relative to bionanotechnology.
0 · Reply
STRAYNUT
STRAYNUT Sep. 10 at 10:30 PM
$NNVC Short Interest (08/31/26) Shares Sold Short 646,145 Change from Last -26.08% Percent of Float 2.59% https://www.wsj.com/market-data/quotes/NNVC
0 · Reply
STRAYNUT
STRAYNUT Sep. 10 at 9:36 PM
$NNVC Part 1 BPh's solution to the Ebola outbreak in the Eastern DRC is a trial that was started in early July and has already infused 300 patients, with 700 more patients required, according to the WHO. Called the PARTNERS trial, between Gilead Sciences and Mapp Bio, it is divided into 4 sub-groups: Control, MBP134 Infusion, Remdesivir Infusion, and the combo of the two drugs together. You would think if they had great results in these first 60 days, they would be forthcoming with that news.
0 · Reply
STRAYNUT
STRAYNUT Sep. 10 at 9:30 PM
$$NNVC Part 2 Now contrast that ineffectual effort with the need for a quick-acting drug, such as NV-387, which will cure the patient in a matter of days. The importance of that feature is apparent when you consider the speed in which this Bundibugyo strain of ebolavirus attacks the body. It takes only 21 days for an infected patient to develop symptoms (fever, headache, tiredness) and only another 21 days from confirming infection to death. Nano is the only biotech in the world that is poised to validate NV-387 in a short and decisive clinical trial, with sufficient Oral Gummies already on site.
0 · Reply
drkazmd65
drkazmd65 Sep. 10 at 12:44 PM
$NNVC - Agreed in principle. However, until the trial IS ACTUALLY underway, we are dead in the water here. I won't be satisfied until and unless there is a PR stating that dosing has commenced.
0 · Reply
Love1010
Love1010 Sep. 9 at 9:42 PM
$NNVC Straynut pumping so down she blows
0 · Reply
STRAYNUT
STRAYNUT Sep. 9 at 7:32 PM
$NNVC NNVC: Part 1. Let me describe to you the most probable winner in the quest for a drug that will improve survival from the rare Bundibugyo Ebolavirus now out of control in the Eastern 6 provinces of the Democratic Republic of Congo (DRC) where the untreated fatality rate is now 48% for adults and 60%+ for children. Only NNVC is offering an oral drug, NV-387, in contrast to others that are infusions, which is extremely advantageous in the epidemic scenario that is now unfolding.
0 · Reply
STRAYNUT
STRAYNUT Sep. 9 at 7:32 PM
$NNVC Part 2 The Oral Gummies are manufactured in six-packs at the Shelton, Ct. lab, and since they are administered one each morning by placing the Gummy on the tongue and simply letting it melt there without swallowing, you can imagine how easy it will be to scale to hundreds of patients at a time if need be. I assign a probability of 90% that it will work perfectly and require only 12 days (2 six-packs) to cure the infected patient, which will astound the medical community, and send the NNVC market cap, currently at $28 million, to at least $150-300 million overnight.
0 · Reply
STRAYNUT
STRAYNUT Sep. 9 at 7:27 PM
$NNVC This is a link to the Pan African Clinical Trials Registry (pactr.samrc.ac.za) database. The unique identification number for this clinical trial is PACTR202608748555077. https://pactr.samrc.ac.za/Search.aspx
0 · Reply
Oinkydollars
Oinkydollars Sep. 8 at 9:23 PM
$NNVC this be like Moderna. Hold on enjoy the ride.
1 · Reply
STRAYNUT
STRAYNUT Sep. 8 at 1:44 PM
$NNVC Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/clinical-trial-for-an-oral-drug-to-treat-ebola-is-registered-in-the-p-1217962
1 · Reply
YoloAlfred
YoloAlfred Sep. 8 at 12:53 PM
$NNVC The trial will show Great Results
0 · Reply
YoloAlfred
YoloAlfred Sep. 8 at 12:52 PM
$NNVC added more....
0 · Reply
YoloAlfred
YoloAlfred Sep. 8 at 12:45 PM
$NNVC dosing starts in 1 to 2 weeks with drug already on site
1 · Reply
YoloAlfred
YoloAlfred Sep. 8 at 12:44 PM
$NNVC news today
1 · Reply
YoloAlfred
YoloAlfred Sep. 8 at 12:41 PM
$NNVC news added..
0 · Reply
STRAYNUT
STRAYNUT Sep. 5 at 6:39 PM
$NNVC: Relative to the stock market swoon, the last two weeks in particular, I am nauseated by witnessing so many retail investors panicking at exactly the wrong time. Nano (Dr. Anil Diwan) is FINALLY on the cusp of initiating his first Phase II trial to save the lives of Congolese infected with the Ebola virus. There is no doubt in my mind that the Oral Gummies will work perfectly, since the "nanoviricides", billions of which are in each Gummy, are the same size as the virus particle and circulate only in the bloodstream. Therein, mimicking the docking portal of the human cell with ligands tailored specifically, the virus is faked out and attaches itself and is then enveloped and destroyed.
1 · Reply
STRAYNUT
STRAYNUT Sep. 5 at 6:38 PM
$NNVC On August 17th, the last PR from Dr. Diwan highlighted the identity of the principal investigator, Dr. Patrick Katoto, Associate Professor of Medicine, Epidemiology, and Global Health at Catholic University of Bukavu, DRC, whose credentials are impeccable. Additionally, the drug product from Nano for the entire clinical trial is on site, and dosing was "expected to occur within a few weeks, barring impediments caused by the very ebola disease outbreak the trial is designed to respond to". EXPECT THE START OF THE TRIAL ANY DAY NOW !!!
0 · Reply
Love1010
Love1010 Sep. 4 at 6:40 PM
$NNVC Is this a real biotech company? No trial notices. No placebo controls. No doubleblind. No endpoints. Truly a joke.
0 · Reply
STRAYNUT
STRAYNUT Sep. 2 at 11:17 PM
$NNVC Gopio-Ct To Honor Five Indian American Achievers At Its 20th Anniversary https://www.theindianpanorama.news/gopio-ct-to-honor-five-indian-american-achievers-at-its-20th-anniversary/
0 · Reply
STRAYNUT
STRAYNUT Aug. 31 at 11:24 PM
$NNVC While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles https://finance.yahoo.com/healthcare/articles/while-measles-cases-continue-increase-123000014.html
0 · Reply